DV
Dividend Vision

LYEL — Lyell Immunopharma Inc

Lyell Immunopharma Inc (LYEL)

Total return is -95.9% over the past 5.2 years, 193.4 points behind SPY at 97.5%. Its deepest 1-year drawdown was 69.9%.

LYEL is an equity stock that tracks Lyell Immunopharma Inc, a single-stock holding rather than a diversified fund. The security does not currently offer a distribution rate or regular dividend distributions. With an inception date of June 2021, this holding appeals primarily to investors seeking exposure to a specific immunopharmaceutical company rather than those focused on income generation through dividends.

LYEL key facts

Asset type
Stock
Asset class
Equity
Inception date
06/17/2021
Last close
$13.95
Market cap
$316,596,320
Average volume
106100.0
Beta
-0.062
Payout ratio
0.0
Forward P/E
0.0
EPS
$-13.62